() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: WAYL

Wayland Group Confirms “BfARM” award for German Cannabis production

May 21, 2019 (GLOBE NEWSWIRE) -- Wayland Group Corp. (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) today announced that its joint venture DEMECAN GmbH (“DEMECAN”), of which it holds 50% with an option to increase to 60% has been awarded three lots of domestic cannabis production in Germany by the Federal Institute for Drugs and Medical Devices (“BfArM”), after the withdrawal of a competitor’s complaint following an oral court hearing.   
Read more

Wayland Addresses Transaction with ICC International Cannabis Corp.

May 02, 2019 (GLOBE NEWSWIRE) -- Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) confirms that any failure-to-file cease trade order (“FFCTO”) derived from the Company’s delay in annual filings will not materially affect the Company’s sale of a 49.9% interest in its international asset and license portfolio to ICC International Cannabis Corp (the “Transaction”).
Read more

Wayland Group Announces Anticipated Delay in Annual Filings

April 23, 2019 (GLOBE NEWSWIRE) -- Wayland Group Corp. (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) announced today that it anticipates a delay in filing its audited annual financial statements for the year ended December 31, 2018, the related management’s discussion and analysis and certificates of its CEO and CFO (collectively, the “Required Filings”) with Canadian securities regulators until after the April 30, 2019 filing deadline.
Read more